Adiponectin Reduces Plasma Triglyceride by Increasing VLDL Triglyceride Catabolism
Liping Qiao 1 ,
Chenhui Zou 1 ,
Deneys R. van der Westhuyzen 1 2 and
Jianhua Shao 1
1 Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, Kentucky
2 Department of Internal Medicine and Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky
Corresponding author: Jianhua Shao, jianhuashao{at}uky.edu
Abstract
OBJECTIVE —Adiponectin is an adipocyte-derived hormone that plays an important role in glucose and lipid metabolism. The main aims of
this study are to investigate the effects of adiponectin on VLDL triglyceride (VLDL-TG) metabolism and the underlying mechanism.
RESEARCH DESIGN AND METHODS —Adenoviruses were used to generate a mouse model with elevated circulating adiponectin. HepG2 and C2C12 cells were treated
with recombinant human adiponectin.
RESULTS —Three days after Ad-mACRP30 adenovirus injection, plasma adiponectin protein levels were increased 12-fold. All three main
multimeric adiponectin molecules were proportionally elevated. Fasting plasma TG levels were significantly decreased (∼40%)
in the mice with elevated adiponectin in circulation, as were the plasma levels of large and medium VLDL subclasses. Although
apolipoprotein B mRNA levels were robustly suppressed in the livers of adiponectin-overexpressing mice and in cultured HepG2
cells treated with recombinant human adiponectin, hepatic VLDL-TG secretion rates were not altered by elevated plasma adiponectin.
However, Ad-mACRP30–treated mice exhibited a significant increase of postheparin plasma lipoprotein lipase (LPL) activity
compared with mice that received control viral vector. Skeletal muscle LPL activity and mRNA levels of LPL and VLDL receptor
(VLDLr) were also increased in Ad-mACRP30–treated mice. Recombinant human adiponectin treatment increased LPL and VLDLr mRNA
levels in differentiated C1C12 myotubes.
CONCLUSIONS —These results suggest that adiponectin decreases plasma TG levels by increasing skeletal muscle LPL and VLDLr expression
and consequently VLDL-TG catabolism.
Footnotes
Published ahead of print at http://diabetes.diabetesjournals.org on 28 March 2008.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work
is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of thi...

Adiponectin Reduces Plasma Triglyceride by Increasing VLDL Triglyceride Catabolism

10.2337/db07-0435